Biocept Q1 Revenues Rise on Test Volume Increases | GenomeWeb

NEW YORK (GenomeWeb) - Biocept reported after the close of the market Thursday that its first quarter revenues increased 47 percent year over year, primarily due to growing commercial test volume.

For the three months ended March 31, the company's total revenues rose to $221,369 from $150,002 the prior year's quarter.

The liquid biopsy firm said it tested 810 billable samples during the first quarter of 2016, up from 289 billable cases during the first quarter of 2015.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.